A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance
dc.contributor.author | Merriel, SWD | |
dc.contributor.author | Moon, D | |
dc.contributor.author | Dundee, P | |
dc.contributor.author | Corcoran, N | |
dc.contributor.author | Carroll, P | |
dc.contributor.author | Partin, A | |
dc.contributor.author | Smith, JA | |
dc.contributor.author | Hamdy, F | |
dc.contributor.author | Moore, C | |
dc.contributor.author | Ost, P | |
dc.contributor.author | Costello, T | |
dc.date.accessioned | 2021-01-27T10:02:46Z | |
dc.date.issued | 2021-02-04 | |
dc.description.abstract | Background Active surveillance (AS) is a management option for men diagnosed with lower risk prostate cancer. There is wide variation in all aspects of AS internationally, from patient selection to investigations and follow-up intervals, and a lack of clear evidence on the optimal approach to AS. This study aimed to provide guidance for clinicians from an international panel of prostate cancer experts. Methods A modified Delphi approach was undertaken, utilising two rounds of online questionnaires followed by a face-to-face workshop. Participants indicated their level of agreement with statements relating to patient selection for AS via online questionnaires on a 7-point Likert scale. Factors not achieving agreement were iteratively developed between the two rounds of questionnaires. Draft statements were presented at the face-to-face workshop for discussion and consensus building. Results 12 prostate cancer experts (9 Urologists, 2 academics, 1 radiation oncologist) participated in this study from a range of geographical regions (4 USA, 4 Europe, 4 Australia). Complete agreement on statements presented to the participants was 29.4% after Round One and 69.0% after Round Two. Following robust discussions at the face-to-face workshop, agreement was reached on the remaining statements. PSA, PSA density, Multiparametric MRI, and systematic biopsy (with or without targeted biopsy) were identified as minimum diagnostic tests required upon which to select patients to recommend AS as a treatment option for prostate cancer. Patient factors and clinical parameters that identified patients appropriate to potentially receive AS were agreed. Genetic and genomic testing was not recommended for use in clinical decision-making regarding AS. Conclusions The lack of consistency in the practice of AS for men with lower risk prostate cancer between and within countries was reflected in this modified Delphi study. There are, however, areas of common practice and agreement from which clinicians practicing in the current environment can use to inform their clinical practice to achieve the best outcomes for patients. | en_GB |
dc.identifier.citation | Vol. 21, article 18 | en_GB |
dc.identifier.doi | 10.1186/s12894-021-00789-5 | |
dc.identifier.uri | http://hdl.handle.net/10871/124516 | |
dc.language.iso | en | en_GB |
dc.publisher | BMC | en_GB |
dc.rights | © The Author(s) 2021. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. | |
dc.subject | Prostate Cancer | en_GB |
dc.subject | Cancer Treatment Protocols | en_GB |
dc.subject | Patient Selection | en_GB |
dc.subject | Active Surveillance | en_GB |
dc.title | A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2021-01-27T10:02:46Z | |
dc.identifier.issn | 1471-2490 | |
dc.description | This is the final version. Available on open access from BMC via the DOI in this record | en_GB |
dc.description | Availability of data and materials: The datasets generated and/or analysed during the current study are not publicly available as consent was not sought from participants to make data publically available. Data may be available from the corresponding author on reasonable request. | |
dc.identifier.journal | BMC Urology | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | en_GB |
dcterms.dateAccepted | 2021-01-20 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2021-01-20 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2021-01-25T16:51:40Z | |
refterms.versionFCD | AM | |
refterms.dateFOA | 2021-02-23T11:14:49Z | |
refterms.panel | A | en_GB |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © The Author(s) 2021. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.